In a recent interview with the World Trademark Review (WTR), Principal Christian Bolduc discusses Bill 96 and its Regulations, and the implications for those doing business in Québec. On June 1, 2022, the Québec...

During a recent meeting, the Canadian Intellectual Property Office (CIPO) revealed plans for a significant reduction in the first examination of Canadian trademark applications not using the pre-approved list of goods...

In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron's application to add an inventor to its issued patent, which was the subject of pending...

In view of the ongoing COVID-19 pandemic, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design

In an interesting factual situation concerning the scope of moral rights, the Quebec Court of Appeal, in 91439 Canada ltée (Éditions de Mortagne) c. Robillard, 2022 QCCA 76...

Since the beginning of the pandemic, the Food and Drug Administration (FDA) has been at a rapid pace in evaluating COVID-19 related diagnostic tests, amongst which include those that utilize patented technologies.

A Federal Court Order has issued on a motion to strike brought by Sandoz in four actions relating to infringement of rituximab patents.

As previously reported, the Federal Court (FC) dismissed Janssen's application for judicial review of the decision of the Office of Submissions and Intellectual Property (OSIP) refusing to list...

On May 28, 2026, the Government of Canada launched a public consultation on the scope of the geographical indications (GIs) regime under the Trademarks Act. The consultation seeks stakeholders' views on how Canada's GI regime could be strengthened and modernized, including whether its scope should be expanded beyond its current categories of protected products.

In a recent interview with CBC News on the cultural appropriation of Inuit designs, Associate Meika Ellis emphasizes the importance of respecting the Inuit community and their cultural heritage.

On January 14, 2020, the Federal Court released a decision by Phelan J. in patent infringement actions pursuant to subsection 6(1) of the Patented Medicines

In an action commenced by Allergan against Apotex in respect of ulipristal (Allergan's FIBRISTAL) under the Patent Medicines (Notice of Compliance) Regulations (PMNOC ...

The balance of Pfizer's motion to dismiss has been deferred to the trial in the liability phase of the proceeding.

Bill 96 was tabled today by the Government of Quebec proposing sweeping revisions to the Quebec's Charter of the French Language

In September 2017, the Patented Medicine Prices Review Board (PMPRB) decided that Alexion's SOLIRIS (eculizumab) was sold at an excessive price. In doing so, the Board departed from the Guidelines...

As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott's decision that the relevant claims of its filgrastim (NEUPOGEN)

As previously reported, the Federal Court of Appeal dismissed Apotex's appeal of a decision relating to macitentan (Janssen's OPSUMIT), which found that Apotex would induce infringement of Janssen's patent.

Eli Lilly seeks leave in olanzapine section 8 damages action.

REVLIMID (lenalidomide): Celgene v Taro.

We now have the first Undertaking involving alleged text message violations of Canada's Anti-Spam Legislation ("affectionately" known as CASL).